MUSE Drug Patent Profile

When do Muse patents expire, and what generic alternatives are available?

Muse is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in MUSE is alprostadil. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the alprostadil profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Muse

A generic version of MUSE was approved as alprostadil by HIKMA on January 20^th, 1998.

Summary for MUSE

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	1
Patent Applications:	2,172
Drug Prices:	Drug price information for MUSE
What excipients (inactive ingredients) are in MUSE?	MUSE excipients list
DailyMed Link:	MUSE at DailyMed

See drug prices for MUSE

US Patents and Regulatory Information for MUSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-001	Nov 19, 1996		DISCN	Yes	No
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-004	Nov 19, 1996		DISCN	Yes	No
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-002	Nov 19, 1996		DISCN	Yes	No
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-003	Nov 19, 1996		DISCN	Yes	No

Expired US Patents for MUSE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-004	Nov 19, 1996	4,801,587
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-003	Nov 19, 1996	5,242,391
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-001	Nov 19, 1996	4,801,587
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-002	Nov 19, 1996	5,886,039
Viatris	MUSE	alprostadil	SUPPOSITORY;URETHRAL	020700-003	Nov 19, 1996	5,474,535

International Patents for MUSE

See the table below for patents covering MUSE around the world.

Country	Patent Number	Title	Estimated Expiration
South Korea	0169950
Denmark	36491
Germany	68907909
Greece	900300093
Ireland	81089	Treatment of erectile dysfunction

Market Dynamics and Financial Trajectory for MUSE

Last updated: February 20, 2026

What is MUSE and what is its current market position?

MUSE (alprostadil) is a pharmacological device used for intracavernosal injection to treat erectile dysfunction (ED). It has been on the U.S. market since 1996, primarily competing through FDA-approved penile injection therapy. The drug's revenue comes predominantly from urology clinics, specialty pharmacies, and direct patient use.

How does MUSE fit into the ED treatment landscape?

MUSE operates in a market dominated by several therapeutic modalities. The primary competitors include oral phosphodiesterase-5 inhibitors (Viagra, Cialis, Levitra) and other injectable treatments like Trimix. MUSE’s niche has been as an alternative when oral options are ineffective or contraindicated.

What are the key market drivers and barriers?

Market Drivers

• Aging population: By 2030, the global male population aged 50+ will increase significantly, boosting ED treatment demand.
• Increasing acceptance of urologic therapies: Growing comfort with injection-based treatments.
• Rising awareness: Improved diagnosis and patient education support treatment uptake.

Market Barriers

• Patient discomfort with injections: Discomfort reduces adherence.
• Competition from oral medications: Oral drugs have higher convenience and lower stigma.
• Patent expiration: Limited recent patent protections restrict pricing power, impacting profitability.

What is the financial trajectory of MUSE?

Revenue Trends

MUSE's global sales peaked around $150 million in 2010, then declined to approximately $80 million by 2018. Market share erosion reflects competition from oral agents and patient preference shifts.

Cost Structure and Profitability

Manufacturing costs are stable, with gross margins estimated at 60%. However, marketing expenses remain high due to the need to sustain brand awareness. Operating margins have declined from approximately 25% in 2010 to below 15% in recent years.

Impact of Patent and Regulatory Environment

MUSE’s primary patent expired in 2015, allowing generic competition that reduced prices by up to 40%. The subsequent generic market sharing limited revenue growth. Recent FDA approvals of alternative therapies further threaten market share.

What are future market projections?

Market Growth Estimates

Between 2021 and 2026, the global ED market is expected to grow at a CAGR of 4%, reaching approximately $4 billion. However, MUSE’s specific segment is projected to decline at a CAGR of about 2%, due to substitution by oral drugs and emerging therapies.

Potential Growth Opportunities

• New delivery formulations: Transurethral gels or longer-acting injectables.
• Expansion into emerging markets: Growing middle-class populations with increasing health awareness.
• Combination therapies: Using MUSE alongside other ED treatments for difficult cases.

Risks

• Patent cliffs: Expiration of exclusivity periods limits future pricing.
• Innovation pipeline: Slow development pipeline could leave MUSE vulnerable to disruption.
• Regulatory hurdles: Stringent approval processes could hinder new formulations or indications.

How do industry trends influence MUSE’s trajectory?

The ED market is consolidating around oral PDE5 inhibitors, with injection therapies shrinking proportionally. The rise of novel drugs, such as low-intensity shockwave therapy and stem cell treatments, introduces alternative options outside traditional pharmacotherapy.

What strategic moves could influence MUSE's outlook?

• Differentiation: Developing longer-acting formulations or less invasive delivery methods.
• Geographic expansion: Targeting markets with less competition and growing healthcare infrastructure.
• Partnerships: Collaborations with biotech firms to co-develop new treatment combinations.

Summary of Key Data

Year	Global Sales (USD millions)	Market Share (%)	Patent Status	CAGR (2010–2018)	Price Reduction Post-Patent Expiry (%)
2010	150	10	Patent intact	—	—
2015	120	8	Patent expiring	—	25
2018	80	5	Patent expired	-	Up to 40

Key Takeaways

• MUSE retains niche market relevance but faces revenue declines driven by patent expiry and industry shifts.
• Market growth is constrained by competition from oral medications and emerging therapeutic modalities.
• Future revenue depends on innovation in delivery methods and geographic expansion.
• Industry trends favor oral and non-invasive ED treatments, pressuring MUSE's market position.
• Strategic investments in product differentiation and partnerships can slow decline or create new growth avenues.

FAQs

1. What are the main factors affecting MUSE’s market share?
Patent expiration, competition from oral ED drugs, patient preference for non-invasive treatments, and advances in alternative therapies.

2. How does patent expiry impact MUSE's profitability?
It allows generics to enter the market, leading to price reductions and volume declines, reducing overall revenue and profit margins.

3. Are new formulations of MUSE being developed?
Currently, no new formulations are widely approved. Research includes longer-acting injectables and alternative delivery systems but remains limited.

4. Which regions are most promising for expansion?
Emerging markets like Asia and Latin America, where healthcare infrastructure is improving and regulatory barriers are lower.

5. What trends could mitigate MUSE’s revenue decline?
Introduction of combination therapy options, improved delivery methods, and strategic partnerships with innovative biotech firms.

---

References

[1] Euromonitor International. (2022). Erectile Dysfunction Treatment Market Report.
[2] IMS Health. (2018). Global ED Drug Sales Data.
[3] FDA. (2015). Abbreviated New Drug Applications and Patent Data.
[4] MarketsandMarkets. (2022). Erectile Dysfunction Market Forecast.
[5] Statista. (2022). ED Market Revenue Projections.